SoFi CEO enters prepaid forward contract on 1.5 million shares
PHILADELPHIA - Context Therapeutics Inc. (NASDAQ:CNTX), a clinical-stage biopharmaceutical company with a market capitalization of approximately $79 million, announced promising preclinical data for its cancer treatment, CT-95, at the American Association for Cancer Research Annual Meeting 2025 in Chicago. Trading at $0.88 per share, InvestingPro analysis suggests the stock is currently undervalued, with analyst price targets ranging from $4 to $9. The company’s research indicates CT-95’s potential effectiveness in targeting mesothelin-expressing cancers such as pancreatic, ovarian, and mesothelioma.
CT-95 is a mesothelin x CD3 bispecific antibody designed to direct T-cell-mediated attack towards malignant cells displaying the mesothelin protein. Mesothelin is overexpressed in about 30% of solid tumors. CT-95’s unique approach involves selective binding to a specific part of the mesothelin protein, which is close to the cell membrane, and avoiding interaction with shed mesothelin, which can hinder the effectiveness of targeted therapies.
The preclinical studies suggest that CT-95 can activate T cells to attack cancer cells without triggering a broad release of cytokines, which can lead to side effects. This selective activation is seen as a key advantage in the safety and tolerability of the treatment.
Context Therapeutics has recently initiated a Phase 1 clinical trial in the United States and expects to release initial clinical data by mid-2026. The trial aims to evaluate the safety and efficacy of CT-95 in patients with mesothelin-expressing cancers.
The findings from the preclinical studies provide a foundation for the ongoing clinical trial and offer hope for addressing the high unmet need for effective treatments in mesothelin expressing cancers.
The details of the CT-95 clinical trial (NCT06756035) are available on clinicaltrials.gov, and further information about the company and its pipeline of T cell engaging bispecific antibodies can be accessed on Context Therapeutics’ website.
This article is based on a press release statement by Context Therapeutics Inc. and presents the information without endorsement of the claims. Investors and interested parties are encouraged to follow the development of CT-95 and its clinical progress. With the company’s next earnings report due in 7 days and a beta of 2.18 indicating higher volatility than the market, subscribers to InvestingPro can access 8 additional exclusive insights and real-time financial metrics to make more informed investment decisions.
In other recent news, Context Therapeutics has been the focus of analyst attention with significant developments in its clinical programs. William Blair initiated coverage of Context Therapeutics with an Outperform rating, highlighting the potential of the company’s novel T-cell engagers (TCEs). These TCEs are currently in dose-escalation trials, aiming to target solid tumors, and could lead to a substantial increase in the company’s value. Meanwhile, JMP Securities reaffirmed a Market Outperform rating, maintaining a $4.00 price target for Context Therapeutics. The company concluded 2024 with $94.4 million in cash and cash equivalents, supporting its operations through two interim clinical readouts and extending into 2027. Context Therapeutics is preparing to move its second asset into clinical trials by the second quarter of 2025, focusing on bispecific TCE antibodies to address limitations in traditional therapies. The company is also set to release the first dataset from its CTIM-76 study, targeting CLDN6-positive cancers, which include ovarian, endometrial, and testicular cancers. These developments underscore the strategic advancements Context Therapeutics is making in the biopharmaceutical sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.